BHCM
XBIT icon

Brevan Howard Capital Management’s XBiotech XBIT Stock Holding History

Brevan Howard Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,578
Closed -$167K – 1436
2024
Q1 		$167K Buy
+20,578
New +$118K ﹤0.01% 834

Other funds holding XBIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brevan Howard Capital Management's XBIT Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of XBiotech (XBIT) in Q2 2024, closing a stake of 20,578 shares — an estimated $167K sold.

Brevan Howard Capital Management first reported a position in XBIT in Q1 2024 and held it in 1 quarter. The position peaked at $167K in Q1 2024. 46 funds tracked by Wall St. Rank hold XBIT as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining XBiotech position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 20,578 XBiotech shares in Q2 2024, an estimated $167K.
  • Brevan Howard Capital Management first reported a position in XBiotech in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's XBiotech position peaked at $167K in Q1 2024.
  • 46 funds tracked by Wall St. Rank held XBiotech as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.